Last updated: 2026-09-06 09:38:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Adaptive Biotechnologies Corporation (ADPT) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $24,30, with a market capitalization of $3,87B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $12,00 to $26,87. This page covers its latest market performance, valuation, price trends and company information.
$3,87B | |
$24,06 | |
$123,97 | |
$0,90 | |
$24,57 | |
1,14M | |
2,90M | |
-- | |
$26,87 | |
$12,00 | |
-- | |
-- |
Adaptive Biotechnologies Corporation (ADPT) last closed at $24,57 as of 2026-09-04 23:53:00, unchanged from the previous close of $24,57.
During the latest regular trading session, ADPT traded between $0,90 and $123,97, with a volume of 1,14M shares. The closing price was near the lower end and near the upper end of its 52-week range.
Over the past seven days, Adaptive Biotechnologies Corporation (ADPT) moved from $26,44 to $24,30, representing a decline of 8,11% ($2,14).
The stock traded between $23,84 and $26,87 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1,79 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 82,7%
ADPT is currently trading at $24,30, placing it 82,7% of the way from its 52-week low of $12,00 to its 52-week high of $26,87. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 624 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Adaptive Biotechnologies Corporation (ADPT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.